Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors (Cholindex)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02623764
Recruitment Status : Active, not recruiting
First Posted : December 8, 2015
Last Update Posted : August 17, 2018
Sponsor:
Collaborator:
Mentis Cura
Information provided by (Responsible Party):
Landspitali University Hospital

Brief Summary:
Drug treatment with cholinesterase inhibitors is indicated for treatment of Alzheimer´s disease and in most cases, one of these drugs is prescribed as soon as the diagnosis has been made. Nevertheless, it has been shown in several studies that up to 30% of patients do not benefit from treatment. These drugs can have side effects, most frequently from the gastrointestinal tract with nausea, diarrhea and discomfort in the abdomen as the most frequent signs. It is therefore important to know before the treatment is initiated if the patient will likely benefit from the drug or not. It is not possible today with current knowledge but this project aims to evaluate a specific index, calculated from an EEG registration (the EEG-cholinergic index) for this purpose. A conventional EEG registration is done before treatment and the cholinergic index calculated from the EEG registration is compared to the clinical outcome. The duration of follow up is 6 months with an extension of further 6 months.

Condition or disease
Alzheimer´s Disease

Detailed Description:

Patients will be recruited in a Memory Clinic. Three possible groups of participants will be offered participation:

  • Those with Mild Cognitive Impairment (MCI) but with biomarkers of Alzheimer´s disease (AD) that are conclusive enough to lead to the diagnosis of AD and to initiate medical treatment.
  • Those with early dementia of AD that are offered medical treatment and are able to give consent.
  • Those with early dementia of Lewy body dementia or Parkinson dementia that are offered medical treatment.

All eligible participants are evaluated by the Mini Mental State Examination (MMSE), Consortium to Establish Registry in Alzheimer´s Disease (CERAD 10 word test; working memory, delayed memory and recognition) and Clock Drawing Test (CDT). In addition, the Addenbrooke test will be used.

Patients with AD irrespective of stage will be offered treatment with donepezil, the most used and cheapest cholinesterase inhibitor in Iceland. The dosis will be as usual, 5mg in the evening for four weeks, then increased to 10mg in the evening.

Patients with Lewy body dementia and Parkinson dementia are offered rivastigmine in patch as this is the only medication with the indication of cognitive impairment in these disorders. The starting dose is 4.6mg/day increased to 9.5mg/day after 4 weeks.

After 3 months, each participant is evaluated again with the same tests as before initiating treatment (continuous variables). The clinical effect is also rated according to Clinical Dementia Rating (CDR; categorical variables). An EEG registration is performed. Adherence to drug therapy as well as evaluation of side effects is registrated.

After 6 months, each participant is evaluated again as after 3 months. This is the primary end point.

After 12 months an additional evaluation is performed by the same instruments (secondary endpoint).

The EEG is thus registrated 3 times (primary end point) or 4 times (secondary end point as the first registration was done during the diagnostic work up before entering the project. The EEG will reveal group wise category (Normal, AD or Lewy according to the third edition (SIGLA) of Mentis Cura). An analysis of the cholinergic index is not revealed to the clinician that is thus blinded to this part of the EEG analysis.

The project will be analysed based on all available information after primary end point. A second analysis will be performed after the second end point.


Layout table for study information
Study Type : Observational
Actual Enrollment : 218 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: EEG-cholinergic Index and Its Validation of Clinical Response to Treatment With Cholinesterase Inhibitors
Study Start Date : December 2015
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine


Group/Cohort
MCI due to Alzheimer´s disease
Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
Mild dementia due to Alzheimer´s disease
Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
Mild dementia due to Lewy body disease
Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment



Primary Outcome Measures :
  1. Change from baseline in Addenbrooke cognitive battery at 3 months and at 6 months [ Time Frame: Baseline, 3 months, 6 months ]
    Addenbrooke cognitive battery will be used before initiating treatment (baseline), after 3 months and after 6 months


Secondary Outcome Measures :
  1. Mini Mental State Examination (MMSE) [ Time Frame: Baseline, 3 months, 6 months ]
    MMSE will be used before initiating treatment (baseline), after 3 months and after 6 months

  2. CERAD-10 word test [ Time Frame: Baseline, 3 months, 6 months ]
    CERAD-10 word test will be used before initiating treatment (baseline) after 3 months and 6 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals diagnosed at a Memory Clinic with Mild Cognitive Impairment or mild dementia due to Alzheimer´s disease or with dementia due to Lewy body disease
Criteria

Inclusion Criteria:

  • Mild Cognitive Impairment or mild dementia due to Alzheimer´s disease or with dementia due to Lewy body disease.

Exclusion Criteria:

  • Too advanced dementia (5 or more on Global Deterioration Scale)
  • likelihood of poor compliance due to social circumstances, drug or alcohol abuse or other defined causes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02623764


Sponsors and Collaborators
Landspitali University Hospital
Mentis Cura
Investigators
Layout table for investigator information
Principal Investigator: Jon Snaedal, MD Professor

Layout table for additonal information
Responsible Party: Landspitali University Hospital
ClinicalTrials.gov Identifier: NCT02623764     History of Changes
Other Study ID Numbers: LSH-15-002
First Posted: December 8, 2015    Key Record Dates
Last Update Posted: August 17, 2018
Last Verified: August 2018

Keywords provided by Landspitali University Hospital:
Alzheimer´s disease
Lewy body dementia
Parkinson dementia
EEG
Cholinergic index

Additional relevant MeSH terms:
Layout table for MeSH terms
Dementia
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinergic Agents
Cholinesterase Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Enzyme Inhibitors